Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A meta-analysis of comparative trials

Journal of Pain and Symptom Management

Volumn 46, Issue 4, 2013, Pages 573-580

  Jandhyala, Ravi ^a   Fullarton, John R ^b   Bennett, Michael I ^c  

^a Cephalon UK Ltd   (United Kingdom)

^b Strategen Ltd   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

breakthrough cancer pain; buccal; Episodic pain; incident pain; rescue medication; sublingual

Indexed keywords

FENTANYL; FENTANYL CITRATE; MORPHINE; PLACEBO;

ANALGESIA; BREAKTHROUGH PAIN; CANCER PAIN; DRUG EFFICACY; DRUG FORMULATION; HUMAN; META ANALYSIS; REVIEW;

BREAKTHROUGH CANCER PAIN; BUCCAL; EPISODIC PAIN; INCIDENT PAIN; RESCUE MEDICATION; SUBLINGUAL;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CAUSALITY; COMORBIDITY; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FENTANYL; HUMANS; MALE; MORPHINE; NEOPLASMS; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84885310819     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.09.009     Document Type: Review

References (35)

1. J. Droney, and J. Riley Recent advances in the use of opioids for cancer pain J Pain Res 2 2009 135 155
2. World Health Organization Cancer pain relief 2nd ed. 1996 World Health Organization Geneva
3. V. Ventafridda, M. Tamburni, and Caraceni A validation study of the WHO method for cancer pain relief Cancer 59 1987 850 856
4. A. Davies, A. Dickman, and C. Reid The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain 13 2009 331 338
5. G. Zeppetella, and M.D.C. Ribeiro The pharmacotherapy of cancer-related episodic pain Expert Opin Pharmacother 4 2003 493 502
6. A. Caraceni, C. Martini, and E. Zecca Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey Palliat Med 3 2004 177 183
7. D.A. Lossignol, and C. Dumitrescu Breakthrough pain: progress in management Curr Opin Oncol 22 2010 302 306
8. A. Dickman Basics of managing breakthrough cancer pain Pharm J 283 2009 213 216
9. M.T. Greco, O. Corli, and M. Montanari Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the Cancer Pain Outcome Research Study Group Clin J Pain 27 2011 9 18
10. S. Mercadante, B.V. Costanzo, and F. Fusco Breakthrough pain in advanced cancer patients followed at home: a longitudinal study J Pain Symptom Manage 38 2009 554 560
11. H. Breivik, N. Cherny, and B. Collett Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes Ann Oncol 20 2009 1420 1433
12. R.K. Portenoy, D. Payne, and P. Jacobsen Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1999 129 134
13. American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. Available from www.painfoundation.org/learn/publications/ files/breakthrough-cancer-pain-report.pdf. Accessed November 2011.
14. B.V. Fortner, G. Demarco, and G. Irving Description and predictors of direct and indirect costs of pain reported by cancer patients J Pain Symptom Manage 25 2003 9 18
15. B.V. Fortner, T.A. Okon, and R.K. Portenoy A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain J Pain 3 2002 38 44
16. G. Zeppetella Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project Palliat Med 25 2010 516 524
17. D.C.J. Vissers, M. Lenre, and K. Tolley An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer Value Health 14 2011 274 281
18. G. Zeppetella Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief J Pain Symptom Manage 35 2008 563 567
19. D. Bennett, A.W. Burton, and S. Fishman Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management Pharm Ther 30 2005 354 361
20. D. Bennett, A.W. Burton, and S. Fishman Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: assessment Pharm Ther 30 2005 296 301
21. A.N. Davies, J. Vriens, and A. Kennett An observational study of oncology patients' utilization of breakthrough pain medication J Pain Symptom Manage 35 2008 406 411
22. R.K. Portenoy, D. Taylor, and J. Messina A randomised, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 2006 805 811
23. N. Slatkin, F. Xie, and J. Messina Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain J Support Oncol 7 2007 327 334
24. R.L. Rauck, M. Tark, and E. Reyes Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2009 2877 2885
25. J.T. Farrar, J. Cleary, and R. Rauck Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 1998 611 616
26. P.H. Coluzzi, L. Schwartzberg, and J.D. Conroy Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain 91 2001 123 130
27. R. Jandhyala, and J.R. Fullarton Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis BMJ Support Palliat Care 2 2012 156 162
28. D.J. Lunn, A. Thomas, and N. Best WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 2000 325 337
29. MRC Biostatistics Unit, Cambridge, UK. The BUGS project. Available from http://www.mrc-bsu.cam.ac.uk/bugs/. Accessed May 18, 2011.
30. Cephalon UK Limited/Teva UK Limited. Clinical Study Report: Study No. 9914. Data on file.
31. Cephalon UK Limited/Teva UK Limited. Clinical Study Report: Study No. 3039. Data on file.
32. Cephalon UK Limited/Teva UK Limited. Study Summary Report. AC 200/013. Data on file.
33. Cephalon UK Limited/Teva UK Limited. Study Summary Report. AC 600/001. Data on file.
34. D. Vissers, W. Stam, and T. Nolte Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer Curr Med Res Opin 26 2010 1037 1045
35. S.M. Weinstein, J. Messina, and F. Xie Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain Cancer 115 2009 2571 2579